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CASE SERIES 
 ORAL SILDENAFIL USE IN NEONATES WITH PERSISTENT 
PULMONARY HYPERTENSION OF NEWBORN 
Ali Shabbir Hussain, Rehan Ali, Shakeel Ahmed, Farah Naz, Anila Haroon 
Department of Pediatrics and Child Health, The Aga khan University Hospital Karachi-Pakistan 
Background: The prevalence of PPHN has been estimated at 1.9 per 1000 live births. After the 
discovery of iNO’s, its efficacy and benefit in PPHN is well established. Even in the best of centers 
equipped with iNo and ECMO the mortality is around 20%. Also, iNO is expensive and difficult to 
administer and monitor which makes it difficult choice in our part of the world. Furthermore About 
40% of patients do not respond or have rebound pulmonary hypertension after discontinuation. Owing 
to these reasons, other treatment modalities like phosphodiesterase inhibitors such as Sildenafil need to 
be evaluated. Methods: We report a retrospective case series of eighteen patients with PPHN admitted 
in NICU and treated with oral sildenafil. Results: Three (17%) babies had mild, 5 (28%) moderate and 
10 (55%) severe PPHN based on echocardiography. Sildenafil was started on all patients on a mean of 
1.67 days and stopped on mean 12.6 days. Initial fio2 was 100%, which after starting sildenafil 
decreased gradually to 40% on mean 10 days. Average length of stay in NICU was 13 days. Twelve 
(67%) patients survived whereas 6 (33%) expired (Figure 2). No improvement in oxygen Index after 36 
hours (p<0.05) was the independent predicting risk factor for PPHN related mortality in the expired 
patients. Conclusion: Oral sildenafil can be a used in conjunction with other treatment modalities for 
PPHN especially in resource limited settings. However further studies regarding its comparative 
efficacy need to be done. 
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INTRODUCTION 
Persistent Pulmonary Hypertension of the Newborn 
(PPHN) is a condition characterized by increased 
pulmonary vascular resistance, extra pulmonary 
shunting of blood from right to left through patent 
circulatory channels (including foramen ovale and 
ductus arteriosus), and consequently, hypo-perfusion of 
lungs.1 The prevalence of PPHN has been estimated at 
1.9 per 1000 live births.1 Physiologically, there is 
maladaptation of the lungs to the extra-uterine condition 
and inadequate transition from fetal to neonatal 
circulation causing abnormal tone and reactivity of 
pulmonary vasculature leading to sustained pulmonary 
hypertension.2 PPHN can result in serious morbidity and 
can be potentially fatal. Even in the best of centers 
equipped with iNo and ECMO the mortality is 20%.3 
We report a case series of eighteen patients with PPHN 
admitted in NICU and treated with sildenafil for 
echocardiogram (ECHO) diagnosed PPHN due to 
unavailability of inhaled nitric oxide (iNO) and 
extracorporeal membrane oxygenation (ECMO).  
Persistent Pulmonary Hypertension of 
Newborn (PPHN) is found in about 0.34–6.8 per 1000 
live births and mortality occurs in 10–20% of the cases.4 
iNO is considered the mainstay of treatment but it is 
often unavailable in resource limited areas. Literature 
also suggests that iNO is sometimes seen to cause 
rebound pulmonary hypertension upon discontinuation.4 
Furthermore, long term use of iNO is not feasible 
because of its short half-life.5,6 Inhaled nitric oxide is 
expensive and difficult to administer and monitor.5 
Moreover, studies show that about 40% of the patients 
may not respond to iNO fully and these patients may 
require additional treatment such as ECMO.5 Also, it is 
known that at oxygenation index (OI) >25, iNO 
decreases the use of ECMO, but does not alter the 
overall mortality.6 Owing to these reasons, other 
treatment options such as Vasodilators; Prostacyclin 
(PGE1), Nitric oxide precursors like L-arginine, Free 
radical scavengers and Phosphodieterase inhibitors such 
as Sildenafil need to be explored for efficacy and safety. 
MATERIAL AND METHODS 
Retrospective review of medical records of all 
neonates admitted in our neonatal intensive care unit 
(NICU) with the diagnosis of PPHN who received 
sildenafil was done after approval from ERC (2743-
Ped-ERC-13). PPHN was suspected based on the 
difference in pre-post ductal oxygen saturations of 
more than 15%, persistent hypoxia defined as Pao2 
<50 mmHg, and oxygen requirement of 100% 
oxygen on admission. Severity of PPHN on ECHO 
was determined by direction of shunt at ductus 
arteriosus and foramen ovale and tricuspid 
regurgitation flow velocity. All Patients with 
underlying congenital heart disease and lung 
hypoplasia were excluded. All neonates who had 
sepsis, evident from positive blood cultures, were 
also excluded. Sildenafil was administered to all 
neonates in oral form with dose of 2 mg/kg/dose 
three times a day. Sildinafil was continued until 
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extubation. OI was calculated at baseline with 
formula: 
FiO2
 × MAP 
PaO2 
Treatment was supplemented with antibiotics, analgesia, 
sedation, and inotropes and suctioning. All babies were 
kept on a minimal-handling status. Variables that were 
recorded include demographic and anthropometric data. 
Other Data include Apgar score at 5 minutes, 
Meconium stained liquor, clinical symptoms, maternal 
comorbid, average length of stay, mortality, need for 
ventilation along with vent settings and chest 
radiographs. Dose and duration of sildinafil were also 
recorded (Table 1). Outcome was assessed by the 
difference in Fio2 requirement after starting sildenafil, 
time taken to get off the ventilator and mortality. 
Secondary out comes were assessed by univariate and 
multivariate analysis. 
RESULTS 
Total of 18 neonates were enrolled out of which 
fourteen were male and four were female. Thirteen 
patients were term (>37 weeks gestation) and five near 
term (35–37 weeks gestation). Four mothers had 
pregnancy induced hypertension (PIH) whereas; one 
mother was diagnosed with gestational diabetes and one 
with urinary tract infection (UTI). Five patients were 
delivered via normal vaginal delivery whereas; ten via 
emergency cesarean section and three via elective 
cesarean section. Eleven out of eighteen patients had 
good APGAR scores at birth. From those who did not 
have good apgar scores, five required immediate 
resuscitation with positive pressure ventilation. Eight 
babies had meconium stained amniotic fluid out of 
which five were suspected to have meconium aspiration. 
All patients required some inotropic support in the form 
of Dopamine (n: 15, 83%), dobutamine (n: 10, 55%) 
and epinephrine (n: 4; 22%). 
Based on echocardiography; 3 (17%) patients 
had mild, 5 (28%) moderate and 10 (55%) severe 
PPHN. Whereas X-ray was reported to be RDS in 5 
(28%) cases. Mean oxygen index (OI) was 44.32 on 
admission. Sildenafil was started on all patients on a 
mean of 1.67 days and stopped on mean 12.6 days. 
Mean starting dose was 5.4 mg/day. Initial fio2 was 
100%, which after starting sildenafil decreased 
gradually to 40% on mean 10 days (Figure 1). Average 
length of stay in NICU was 13 days. Twelve (67%) 
patients survived whereas 6 (33%) expired (Figure 2). 
No improvement in oxygen Index after 36 hours 
(p<0.05) was the independent predicting risk factor for 
PPHN related mortality in the expired patients. 
DISCUSSION 
PPHN is a disease with serious outcomes. The patients 
are often critically ill and need immediate ventilation. 
The pathophysiology of PPHN can be divided into three 
broad categories- increased pulmonary vasoconstriction, 
abnormal pulmonary vascular development, and 
decreased pulmonary vascular bed (lung hypoplasia).5 
Causes that lead to these changes are not fully 
understood but perinatal hypoxia, meconium aspiration, 
acidosis, hypothermia and structural lung malformations 
such as diaphragmatic hernia and maternal use of non-
steroidal anti-inflammatory drugs in the third trimester 
of pregnancy are all associated with increased risk of 
PPHN.5  
Clinical diagnosis of PPHN is made on the 
basis of hypoxemia refractory to oxygen therapy.4 Right 
to left shunting is confirmed with the pre- and post-
ductal oxygen saturation levels.4 Chest radiography is 
used to diagnose the presence of underlying lung 
pathologies such as pneumonia and meconium 
aspiration syndrome. Echocardiography is done to 
confirm the diagnosis with findings of elevated 
Tricuspid Regurgitation (TR) pressures. 
Echocardiography is also done to rule out any 
congenital cardiac anomaly.6  
Several management options are available 
worldwide, including iNO and ECMO.6 Developing 
countries often have problems accessing these facilities. 
In such settings, Sildenafil, a specific Phosphodiesterase 
5 (PDE-5) inhibitor, even when used as a monotherapy, 
seems to be a good treatment option. Despite the fact 
that we have limited knowledge of Sildenafil safety and 
use, we continue to use it because of the limited choices 
neonatologists have for the treatment of PPHN.7  
Sildenafil is a type 5 Phosphodiesterase (PDE) 
inhibitor. Like iNO, Sildenafil is a vasodilator specific 
for pulmonary vasculature.7,8 By inhibiting PDE, 
sildenafil increases the intracellular cAMP and cGMP 
levels, leading to vascular smooth muscle relaxation in 
the pulmonary vascular bed.8 Studies have shown that 
Sildenafil can be used successfully to improve the 
oxygenation parameters in neonates with PPHN.9 
Shah and Ohlsson; in cochrane data base 
(2011) reviewed three RCTs looking at the efficacy of 
sildenafil and concluded that there was significant 
reduction in mortality in sildenafil group. Therefore, 
Sildinafil has significant potential especially in resource 
limiting settings. However, whether sildenafil can 
completely replace iNO as the gold standard of 
treatment for PPHN is still unknown.10  
Baquero et al showed that oral sildenafil 
improved Oxygenation Index in critically sick patients 
with severe degree of PPHN.11 The study however 
concluded that they could not say whether sildenafil 
increased survival in these patients.11 In our study, 
infants admitted with PPHN responded to oral sildenafil 
therapy as evident by decrease in the fractional 
inspiratory Oxygen demand in these patients over a 
period of ten days. We acknowledge that following the 
OI 
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FiO2 may not present a very accurate picture of the 
oxygenation dependence. In our study, we did not look 
for any adverse outcomes of the drug.  
The treatment of PPHN is mainly supportive 
and since the underlying pathology involves hypoxemia 
due to elevated pulmonary vascular resistance, selective 
pulmonary vasodilatation is the aim of medical 
management of PPHN.12,13 Meconium aspiration 
syndrome is one of the most important causes of 
morbidity and mortality in babies with PPHN as 
discussed by Shekerdemian et al.14 However, our study 
showed that meconium aspiration syndrome was present 
in only five patients out of whom two developed severe 
PPHN and three moderate PPHN. Our study reported 
that respiratory distress syndrome is also a most 
common symptom of PPHN.  
Table-1: Patients characteristics and outcomes 
 n (%) 
Gender  
Female 4 (78) 
male 14 (22) 
Gestation  
Term > 37 wks 13 (72) 
Near term 35-37 wks 5 (28) 
Mode of delivery:  
SVD 5 (27) 
Emergency Cesarean section 10 (56) 
Elective Cesarean section 3 (17) 
Apgar at 5 minutes:  
good 11 (61) 
poor 7 (39) 
Immediate resuscitation:  
Dry and stimulate 8 (44) 
PPV 5 (28) 
Intubation and MV 5 (28) 
Meconium stained Liquor 8 (44) 
Meconium Aspiration syndrome 5 (28) 
Clinical Features  
Cyanosis 3 (17) 
Apnea 1 (5) 
Hypothermia/hyperthermia 0 (0) 
Grunting 10 (55) 
Tachypnea 12 (67) 
Signs of respiratory distress 14 (78) 
Bradycardia 3 (17) 
Maternal comorbid  
Pregnancy induced Hypertension 4 (22) 
Gestational Diabetes 1 (5) 
Urinary tract infection 1 (5) 
None 14 (78) 
Associated conditions, number:  
Respiratory distress syndrome 5 (28) 
Meconium aspiration Syndrome 5 (28) 
Pneumonia 1 (5.6) 
NEC 0 (0) 
IVH 0 (0) 
inotropic Support 15 (83) 
Dopamine 15 (83.3) 
Dobutamine 10 (55) 
Adrenaline 4 (22) 
Average Length of stay (days) 12.4 
Outcome  
Survived 12 (67) 
Expired 6 (33) 
 n (%) 
Severity of PPHN based on echo  
 Mild 3 (17) 
 Moderate 5 (28) 
 Severe 10 (55) 
Ventilator Mode:  
 SIMV 11 (61) 
 CMV 2 (11) 
 HFO 5 (27) 
Mean oxygenation index on admission 44.32 
Mean Airway Pressure 18 
Chest Radiograph:  
 Normal 3 (16) 
 RDS 9 (50) 
 Pulmonary Edema 1 (5.6) 
 PIE 1 (5.6) 
 MAS 1 (5.6) 
 Pneumothorax 1 (5.6) 
 Atelactasis 1 (5.6) 
 Image not available 1 (5.6) 
Sildenafil   
 started at day of life (Mean) 1.67 
 Stopped at day of life (Mean) 12.6 
 Dose (mean dose in mg/kg/day) 5 
 Initial Fio2 when sildenafil started  0.1 
Mean duration of mechanical ventilation in 
days 
10 
Average length of stay in NICU in days 13 
 
 
Figure-1: Decrease in oxygen requirement in days 
following sildenafil administration 
 
Figure-2: Outcomes according to the severity of 
PPHN based on ECHO 
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CONCLUSION 
Current literature suggests good evidence of the use 
of sildenafil in PPHN8. The findings of this study 
suggest that oral sildenafil can be successfully used 
to improve oxygenation in patients with PPHN 
especially in a resource-limited setting where 
facilities like ECMO and inhaled nitric oxide are not 
available. With sildenafil effectively lowering the 
oxygen requirement and probably improving the 
mortality rate in these patients, there is a possibility 
of concluding the need for the more sophisticated 
modalities. However, these findings cannot be 
generalized because small sample size. We also 
acknowledge that our study could not adequately rule 
out the possibility of side effects associated with 
sildenafil use. COI statement: The authors have no 
conflicts of interest relevant to this article. 
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